ebook_ADHD2019_engl.

60 Rohde, Buitelaar, Gerlach & Faraone lence (NICE) ADHD guideline was launched in March 2018. Besides important rules regarding diagnosis (e.g., do not forget to assess parent mental health when assessing ADHD in children), the NICE guidelines offer relevant information on recognition, identification and how to give support for those affected by the disor- der, their families and carers. The NICE guideline can be downloaded at National Institute for Health and Care Excellence. 33 The 4 th edition of the Guidelines of the Canadian ADHD Resource Alliance (CADDRA) was launched in February 2018. Whilst this guideline was not as rigorous in its development as that NICE guidelines it contains probably the most comprehensive open access tools for hel- ping clinicians systematize the ADHD assessment procedures. It provides useful flowcharts specific for assessment in each developmental stages (children, adoles- cent and adults). It also provides a specific chapter addressing comorbidities and differential diagnoses that is helpful for clinicians since it offers some tables with potential overlapping symptoms and not overlapping symptoms of the co-occur- ring disorders. The CADDRA guidelines can be downloaded at Canadian ADHD Resource Alliance. 34 Conflicts of interest Luis Augusto Rohde has received grant or research support from, served as a consultant to, and ser- ved on the speakers’ bureau of Eli Lilly and Co., Janssen, Medice, Novartis and Shire. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by Dr Rohde have received unrestricted educational and research support from the following pharmaceutical companies: Eli Lilly and Co., Janssen, and Novartis. Dr Rohde has received authorship royalties from Oxford Press and ArtMed and travel grants from Shire to take part in the 2018 APA annual meeting and from Novartis to take part of the 2016 AACAP annual meeting. David Coghill reports grants from The European Union FP7 Programme and Shire; honoraria from Shire, Eli-Lilly, Novartis, and Janssen-Cilag; acted as an advisor to Shire and Lundbeck; and received royalties from Oxford University Press. Prof. Coghill was a member of British Association for Psychopharmacology ADHD, Depression and Bipolar Disorder Guideline groups. Tobias Banaschewski served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, Oxford outcomes, PCM scientific, Shire and Viforpharma. He re- ceived conference support or speaker’s fee by Medice, Novartis and Shire. He is/has been involved in clinical trials conducted by Shire & Viforpharma. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. King’s College London received payments for work conducted by Philip Asherson: consultancy for Shire, Eli-Lilly, Novartis, Lundbeck and Medice; educational and/ or research awards from Shire, Eli-Lilly, Novartis, Vifor Pharma, GW Pharma, and QbTech; speaker at events sponsored by Shire, Eli-Lilly, Janssen-Cilag, Medice and Novartis. REFERENCES 1. Polanczyk G, Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-8.